Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:IRON NASDAQ:KIN NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.59-1.6%$5.39$3.96▼$9.85$2.48B0.412.61 million shs1.05 million shsIRONDisc Medicine$55.86+5.5%$49.74$30.82▼$68.73$1.83B0.76338,737 shs406,535 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsSDGRSchrodinger$21.68+1.2%$22.39$16.60▼$28.47$1.57B1.58918,767 shs1.04 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-2.47%-1.32%+41.26%+33.53%-7.89%IRONDisc Medicine-0.77%+3.60%+5.90%+36.87%+11.52%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%SDGRSchrodinger+3.83%+3.93%-13.00%+9.73%+1.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Cos3.6847 of 5 stars1.93.00.04.02.33.30.6IRONDisc Medicine3.1624 of 5 stars4.51.00.00.03.02.50.0KINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASDGRSchrodinger2.7895 of 5 stars3.42.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.86Reduce$7.4212.54% UpsideIRONDisc Medicine 3.09Buy$96.7073.11% UpsideKINKindred Biosciences 0.00N/AN/AN/ASDGRSchrodinger 2.75Moderate Buy$33.2553.37% UpsideCurrent Analyst Ratings BreakdownLatest KIN, SDGR, BHC, and IRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.007/3/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.007/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.006/17/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/16/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.006/11/2025IRONDisc MedicineRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.005/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.005/2/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/16/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.73B0.25$7.57 per share0.87($0.89) per share-7.40IRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/AKINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29SDGRSchrodinger$207.54M7.67N/AN/A$5.78 per share3.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M-$0.11N/A1.41N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)IRONDisc Medicine-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/ASDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)Latest KIN, SDGR, BHC, and IRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025BHCBausch Health Cos$0.9320N/AN/AN/A$2.47 billionN/A7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CosN/A1.350.97IRONDisc Medicine0.0437.6537.65KINKindred Biosciences0.197.027.02SDGRSchrodingerN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%IRONDisc Medicine83.70%KINKindred Biosciences66.89%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos8.05%IRONDisc Medicine4.24%KINKindred Biosciences13.69%SDGRSchrodinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableIRONDisc Medicine3034.63 million33.17 millionNot OptionableKINKindred Biosciences6345.46 millionN/AOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableKIN, SDGR, BHC, and IRON HeadlinesRecent News About These CompaniesAllspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)July 7 at 3:42 AM | marketbeat.comSDGR - Schrodinger Inc Ordinary Shares Financials - MorningstarJuly 5, 2025 | morningstar.comMMS initiates coverage on AI Biotechs, flags key pipeline catalystsJuly 3, 2025 | investing.comSchrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505July 3, 2025 | msn.comMorgan Stanley Initiates Coverage on Schrodinger (NASDAQ:SDGR)July 3, 2025 | marketbeat.comSchrödinger, Inc. (SDGR) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJuly 2, 2025 | prnewswire.comShort SDGR: Schrödinger bounces from 2024 midpoint, trading range low as potential short-term targetJuly 1, 2025 | invezz.comISumitomo Mitsui Trust Group Inc. Sells 48,103 Shares of Schrodinger, Inc. (NASDAQ:SDGR)July 1, 2025 | marketbeat.comSchrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström MacroglobulinemiaJune 27, 2025 | tmcnet.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 23, 2025 | globenewswire.com17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLCJune 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 18, 2025 | globenewswire.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 17, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 16, 2025 | accessnewswire.comAGAMMA Investing LLC Acquires 117,796 Shares of Schrödinger, Inc. (NASDAQ:SDGR)June 14, 2025 | marketbeat.comSchrödinger: Assessing The Signal And The Noise In The Phase 1 ResultsJune 13, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 13, 2025 | accessnewswire.comAStanley Laman Group Ltd. Acquires 27,511 Shares of Schrödinger, Inc. (NASDAQ:SDGR)June 13, 2025 | marketbeat.comSchrödinger slides after early-stage trial data for cancer therapyJune 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Stocks With Near-Unanimous Buys That Could Rally HigherBy Nathan Reiff | July 2, 2025View 3 Stocks With Near-Unanimous Buys That Could Rally HigherThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideThe Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingBy Leo Miller | July 2, 2025View The Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingKIN, SDGR, BHC, and IRON Company DescriptionsBausch Health Cos NYSE:BHC$6.59 -0.11 (-1.64%) Closing price 03:57 PM EasternExtended Trading$6.52 -0.08 (-1.14%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Disc Medicine NASDAQ:IRON$55.86 +2.89 (+5.46%) Closing price 04:00 PM EasternExtended Trading$55.80 -0.06 (-0.11%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Schrodinger NASDAQ:SDGR$21.68 +0.26 (+1.21%) Closing price 04:00 PM EasternExtended Trading$21.65 -0.03 (-0.16%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
